MedTrace Logo

Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease

NCT03715673 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2020-01-13

No results posted yet for this study

Summary

The investigators are going to study von Willebrand antigen and activity levels in patients with inflammatory bowel disease. The study will be on 46 patients who were diagnosed with inflammatory bowel disease mainly ulcerative colitis and Crohn's disease divided into two arms; group A will include 23 cases with active IBD(cases)status and group B will include 23 cases with inactive IBD status(control) to compare the vWF antigen and activity ( expected to be higher in active disease group.

The investigators will follow all of the patients for any arterial or venous thrombosis to evaluate IBD as a risk factor of thrombosis, on the other hand, they are looking to detect cases of acquired von Willebrand syndrome in some cases with bleeding that not explained by the inflammatory bowel disease status.

The aim of the work:

1. Assessment of VWF antigen in patients with inflammatory bowel disease and correlate it to disease activity.
2. Evaluation of VWF antigen as a risk factor for thrombosis in inflammatory bowel disease patients.
3. Detection of acquired von Willebrand disease in inflammatory bowel disease.

Conditions

  • Inflammatory Bowel Diseases
  • Von Willebrand Diseases

Interventions

DIAGNOSTIC_TEST

von willebrand antigen and activity

Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-10-31
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03715673 on ClinicalTrials.gov